Nanobiotechnology and Nanomedicine Companies
Showing results 1 - 20 of 22 for companies in category Delivery in USA:
Designs, engineers and fabricates coatings, capsules, and "Artificial Cells" from polymers called polypeptides by a method called layer-by-layer self-assembly (LBL).
A biotechnology company engaged in the development and delivery of novel protein and cellular based therapies through design of proprietary Biological Nano Particles.
Develops nanotechnology drug delivery systems based on novel nanomaterials that provide precise control over location and timing of drug delivery.
Developed a technology to compact DNA into complexes containing only a single molecule of DNA, resulting in a volume 30-1000 times smaller than other complexes. This simple difference makes Copernicus' "DNA nanoparticles" highly stable and uniquely able to deliver DNA to the nuclei of non-dividing human cells - which includes most cells in the body.
The Company is developing a pipeline of multifunctional, next-generation therapeutics, binding known anti-cancer agents to its patented colloidal gold tumor-targeting nanotechnology.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company also has developed a microfabricated nanopore device for the sustained release of therapeutic agents.
The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
The company is developing therapeutic immunotherapy by incorporating virus-specific immunogenic DNA into nanoparticles.
The company's focus is on the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases. Their technologies also hold the promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention.
The foundation of the company's IVEC™ drug delivery platform is based on polymer micelle technology, spherical nanosized capsules formed by the assembly of block copolymers in water.
Keystone Nano has an exclusive license to Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles that they call Molecular Dots (MDs). These Molecular Dots can encapsulate drugs and/or fluorescent molecules.
The company utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties.
Develops nanoparticle based in vivo delivery applications.
This start-up is focussed on tumor-specific nanoparticle platforms to largely improve delivery efficiency, treatment efficacy and product safety.
NanoMedical Systems (NMS) is a startup company, which will commercialize the patented research of Dr. Mauro Ferrari at the University of Texas Health Science Center in Houston, a sponsored research site and a source of licensed IP for NMS. The company's Personalized Molecular Drug-delivery System (PMDS) is a small drug delivery device that is implanted subcutaneously (just under the skin) for slow and consistent release of a therapeutic agent over many weeks or months. A nanochannel delivery system (nDS) embodied on a silicon chip regulates the flow of therapeutic molecules.
Develops a therapeutic medical device which incorporates a new class of microparticles/nano-shells to selectively destroy solid tumors.
A nanobio-pharmaceutical company utilizing nanoscale materials and processes to develop anti-viral drugs against a wide range range of human and animal viruses.
PDS Biotechnology Corporation is a biopharmaceutical company applying the company's platform Versamune nanotechnology to a new class of safe, simple, potent and targeted immunotherapies for the treatment of cancer and infectious diseases.
Develops a Protected Graft Copolymer (PGC™) nano-carrier drug delivery system.
The company is specialized in developing cutting-edge nanoparticle technologies for the development of targeted drug delivery systems.